tetano
Editor, Senior Moderator
J Cell Mol Med
. 2021 Mar 10.
doi: 10.1111/jcmm.16431. Online ahead of print.
Association of glycosylated haemoglobin HbA1c levels with outcome in patients with COVID-19: A Retrospective Study
Shuai Yuan[SUP] 1 2 [/SUP], Huaping Li[SUP] 1 2 [/SUP], Chen Chen[SUP] 1 2 [/SUP], Feng Wang[SUP] 1 2 [/SUP], Dao Wen Wang[SUP] 1 2 [/SUP]
Affiliations
Abstract
Patients with hyperglycemia tend to be susceptible to Coronavirus disease 2019 (COVID-19). However, the association of HbA1c level with outcome of COVID-19 patients was unclear. We performed a retrospective study of 2880 cases of COVID-19 admitted in Tongji Hospital, Wuhan, China, among which 922 had detected the HbA1c levels. We found that COVID-19 patients with either lower levels of HbAlc (3%-4.9%) or higher levels of HbAlc (?6%) were associated with elevated all-cause mortality. Meanwhile, we observed that HbAlc levels were highly correlated with haemoglobin (Hb) and total cholesterol (TC) (P < .0001), moderately correlated with albumin (ALB) and high-sensitive C reaction protein (hs-CRP) (0.0001 < P<.001), and relatively low correlated with low-density lipoprotein cholesterol (LDL-C) (.001 < P<.01). These associated cofactors might together contribute to the clinical outcome of COVID-19 patients. Furthermore, the mortality was higher in COVID-19 patients with newly diagnosed diabetes mellitus (DM) compared with COVID-19 patients with history of DM. Moreover, in patients with history of DM, the mortality was decreased in patients treated with anti-hyperglycaemic drugs. In summary, our data showed that the in-hospital mortality was increased in COVID-19 patients with lower or higher levels of HbAlc. Meanwhile, initiation of appropriate anti-hyperglycaemic treatment might improve the clinical outcome in COVID-19 patients.
Keywords: COVID-19; HbAlc; diabetes; mortality.
. 2021 Mar 10.
doi: 10.1111/jcmm.16431. Online ahead of print.
Association of glycosylated haemoglobin HbA1c levels with outcome in patients with COVID-19: A Retrospective Study
Shuai Yuan[SUP] 1 2 [/SUP], Huaping Li[SUP] 1 2 [/SUP], Chen Chen[SUP] 1 2 [/SUP], Feng Wang[SUP] 1 2 [/SUP], Dao Wen Wang[SUP] 1 2 [/SUP]
Affiliations
- PMID: 33694276
- DOI: 10.1111/jcmm.16431
Abstract
Patients with hyperglycemia tend to be susceptible to Coronavirus disease 2019 (COVID-19). However, the association of HbA1c level with outcome of COVID-19 patients was unclear. We performed a retrospective study of 2880 cases of COVID-19 admitted in Tongji Hospital, Wuhan, China, among which 922 had detected the HbA1c levels. We found that COVID-19 patients with either lower levels of HbAlc (3%-4.9%) or higher levels of HbAlc (?6%) were associated with elevated all-cause mortality. Meanwhile, we observed that HbAlc levels were highly correlated with haemoglobin (Hb) and total cholesterol (TC) (P < .0001), moderately correlated with albumin (ALB) and high-sensitive C reaction protein (hs-CRP) (0.0001 < P<.001), and relatively low correlated with low-density lipoprotein cholesterol (LDL-C) (.001 < P<.01). These associated cofactors might together contribute to the clinical outcome of COVID-19 patients. Furthermore, the mortality was higher in COVID-19 patients with newly diagnosed diabetes mellitus (DM) compared with COVID-19 patients with history of DM. Moreover, in patients with history of DM, the mortality was decreased in patients treated with anti-hyperglycaemic drugs. In summary, our data showed that the in-hospital mortality was increased in COVID-19 patients with lower or higher levels of HbAlc. Meanwhile, initiation of appropriate anti-hyperglycaemic treatment might improve the clinical outcome in COVID-19 patients.
Keywords: COVID-19; HbAlc; diabetes; mortality.